PB (MDT)- 3010 (Biosimilar) Diabrid Technology / NobleCleav® Technology
Paras Biopharmaceuticals Finland Oy has developed 4 products (API) for type I and type II Diabetes Mellitus (DM).
The process for the production of insulin "Glargine" and the Diabrid Technology developed for the production of Insulin "Aspart" are currently being prepared for worldwide PCT patent submission. These technological innovations by Paras Biopharmaceuticals Finland Oy reduce the costs of industrial production of Glargine and Insulin "Aspart" achieving higher economic advantages.
| Product status | » SDS-PAGE High expression. » Mass spectrometry : Confirmation of N-and C- terminal, and AA sequence. |
| Technology status | Soon to be available for licensing within scale-up production. Recombinant stable E. Coli Clone exhibits deposits of the Metabolic Disorder Treatment (PB (MDT) – 3010) product inside the cells (EM@39000-Paras Rights Reserved). 
SDS-PAGE-Gel image (left) showing marker (lane1), homogenization broth (lane2) and separation of Metabolic Disorder Treatment product (lane3). |
Paras Biopharmaceuticals
Finland Oy,
Kiviharjunlenkki 10, OULU,
FI-90220 Finland
P: +358 442709462
Dr Ashesh Kumar
E: kumar.ashesh@parasbiopharma.com
P: +358 (0) 400207380
Dr Mark Jackson
E: mark.jackson@parasbiopharma.com
P:+358 (0) 442905993
Skype: Paras.Finland
This website uses cookies; by continuing to use this page, you consent to their use. I Understand About Cookies.
